Teva Pharmaceutical Industries Ltd (TEVJF) — 10-Q Filings
All 10-Q filings from Teva Pharmaceutical Industries Ltd. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Teva Swings to Profit on Revenue Growth, Reduced Impairments
— Nov 5, 2025 Risk: medium
TEVA PHARMACEUTICAL INDUSTRIES LTD reported a significant turnaround in its financial performance for the three and nine months ended September 30, 2025. Net re -
Teva's Q2 Revenue Hit by $32M Derivative Loss; Issues $1.8B in New Debt
— Jul 30, 2025 Risk: high
Teva Pharmaceutical Industries Ltd. reported a significant negative impact from derivative instruments on revenues, totaling $32 million in Q2 2025, a substanti -
Teva Pharma Repays Debt, Goodwill Impairment Nears $30B
— May 7, 2025 Risk: medium
Teva Pharmaceutical Industries Ltd. filed a 10-Q for the period ending March 31, 2025. In January 2025, the company repaid $426 million and $427 million of its -
Teva Pharma Repays Debt, Faces Bond Target Risks
— Nov 6, 2024 Risk: medium
Teva Pharmaceutical Industries Ltd. filed a 10-Q for the period ending September 30, 2024. In October 2024, Teva repaid $685 million of its 1.13% senior notes d -
Teva Pharma Q2: $16M Hedge Gain, Allergan Contingent Consideration Revised
— Jul 31, 2024 Risk: medium
Teva Pharmaceutical Industries Ltd. reported its Q2 2024 results, noting a revision in prior period presentation. A significant event was the termination of a c -
Teva Pharmaceutical Industries Ltd. Files 10-Q for Period Ending March 31, 2024
— May 8, 2024 Risk: medium
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Teva extinguished $631M of 6% senior notes due 2025, $43
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX